Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins
Jerry R. Mendell(Nationwide Children's Hospital), K. Reed Clark(Nationwide Children's Hospital), Laurence Viollet(Nationwide Children's Hospital), Zarife Sahenk(The Ohio State University), Josepha Craenen(Nationwide Children's Hospital), Xiomara Rosales-Quintero(Nationwide Children's Hospital), Janaiah Kota(Ultragenyx Pharmaceutical (United States)), William G. Bremer(Nationwide Children's Hospital), Christopher M. Walker(University of Kansas Medical Center), Sarah Lewis(Nationwide Children's Hospital), Brian D. Coley(Cincinnati Children's Hospital Medical Center), Barry J. Byrne(University of Florida), Gloria Galloway(Nationwide Children's Hospital), Vinod Malik(Nationwide Children's Hospital), Katherine J. Campbell(Nationwide Children's Hospital), Louise R. Rodino‐Klapac(Sarepta Therapeutics (United States)), Christopher Shilling(Nationwide Children's Hospital), Thomas J. Conlon(University of Florida)
Cited by 214
Related Papers
CD8 <sup>+</sup> Lymphocytes Can Control HIV Infection in Vitro by Suppressing Virus Replication
|Science|1986|993
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563